Market Overview

UPDATE: Credit Suisse Initiates Seattle Genetics at Outperform; Antubody Pure-Play

Related SGEN
Seattle Genetics Offers Data Supporting Antibody-Drug Conjugate, Novel Immuno-Oncology Programs at AACR Meeting
The Most Notable Insider Buys And Sells Of Last Week
Seattle Genetics (SGEN) Clay B. Siegall on Q2 2016 Results - Earnings Call Transcript (Seeking Alpha)

Credit Suisse initiated coverage on Seattle Genetics (NASDAQ: SGEN) with an Outperform rating and a $28 price target.

Credit Suisse commented, "We view SGEN as a mustown pure-play antibody company, with a leadership position in the field of antibody-drug conjugates, an area of increasing investor and pharmaceutical company interest. … Data flow at upcoming meetings including ASH in December, EHA and ASCO in June, and ESMO in September will provide venues for updated Adcetris results and new clinical data from the pipeline. The likely accumulation of positive data across multiple drugs should increase confidence in ongoing Phase III trials and the value currently assigned to the technology/pipeline. Quarterly sales are important in the near-term, but not as important as investor confidence in market expansion opportunities"

Seattle Genetics closed at $23.45 on Monday.

Latest Ratings for SGEN

Mar 2016SunTrust Robinson HumphreyInitiates Coverage onNeutral
Feb 2016Cantor FitzgeraldUpgradesHoldBuy
Feb 2016BarclaysMaintainsOverweight

View More Analyst Ratings for SGEN
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (SGEN)

View Comments and Join the Discussion!